Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure.

ABSTRACT:

Background

Soluble urokinase-type plasminogen activator receptor (suPAR) is a marker of immune activation and pathogenic factor for kidney disease shown to predict cardiovascular outcomes including heart failure (HF) in various populations. We characterized suPAR levels in patients with HF and compared its ability to discriminate risk to that of B-type natriuretic peptide (BNP).

Methods and results

We measured plasma suPAR and BNP levels in 3,437 patients undergoing coronary angiogram and followed for a median of 6.2 years. We performed survival analyses for the following outcomes: all-cause death, cardiovascular death, and hospitalization for HF. We then assessed suPAR's ability to discriminate risk for the aforementioned outcomes. We identified 1116 patients with HF (age 6

SUBMITTER: Hayek SS 

PROVIDER: S-EPMC10246488 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature